| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERGIC3 |
| Uniprot No | Q9Y282 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 47-341aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSQYYLTTE VHPELYVDKS RGDKLKINID VLFPHMPCAY LSIDAMDVAG EQQLDVEHNL FKQRLDKDGI PVSSEAERHE LGKVEVTVFD PDSLDPDRCE SCYGAEAEDI KCCNTCEDVR EAYRRRGWAF KNPDTIEQCR REGFSQKMQE QKNEGCQVYG FLEVNKVAGN FHFAPGKSFQ QSHVHVHDLQ SFGLDNINMT HYIQHLSFGE DYPGIVNPLD HTNVTAPQAS MMFQYFVKVV PTVYMKVDGE VLRTNQFSVT RHEKVANGLL GDQGLPGVFV LYELSPMMVK LTEKHRSF |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ERGIC3重组蛋白的3篇参考文献示例(注：文献为虚拟示例，实际需根据真实研究补充)：
1. **文献名称**：*ERGIC3 regulates intracellular protein trafficking and cell migration via interaction with COPII*
**作者**：Zhang L, et al.
**摘要**：研究揭示了ERGIC3重组蛋白通过与COPII囊泡的相互作用调控分泌蛋白运输，并影响肿瘤细胞的迁移能力。
2. **文献名称**：*Crystal structure and functional analysis of human ERGIC3 protein*
**作者**：Wang Y, et al.
**摘要**：首次解析了ERGIC3重组蛋白的晶体结构，发现其C端结构域对维持内质网-高尔基体膜运输的稳定性至关重要。
3. **文献名称**：*ERGIC3 deficiency disrupts collagen secretion and causes skeletal dysplasia*
**作者**：Tanaka K, et al.
**摘要**：利用重组ERGIC3蛋白进行功能挽救实验，证明其缺失导致胶原蛋白分泌异常，与骨骼发育不良相关。
---
**提示**：实际文献需通过PubMed/Google Scholar检索关键词"ERGIC3 recombinant protein"。真实研究多集中于ERGIC3在囊泡运输、分泌通路及疾病模型中的作用机制。
**Background of ERGIC3 Recombinant Protein**
The ER-Golgi intermediate compartment 3 (ERGIC3) is a conserved transmembrane protein primarily localized to the endoplasmic reticulum (ER)-Golgi interface, a dynamic hub for secretory protein sorting, modification, and trafficking. As a component of the ERGIC complex, it plays a critical role in maintaining the structural integrity of this compartment and facilitating vesicular transport between the ER and Golgi apparatus. ERGIC3 is implicated in coordinating COPII-coated vesicle formation at ER exit sites and COPI-mediated retrograde transport, ensuring efficient cargo shuttling.
Structurally, ERGIC3 contains a short N-terminal cytoplasmic domain, a single transmembrane region, and a C-terminal luminal domain with conserved coiled-coil motifs. These motifs mediate interactions with other ERGIC proteins, such as ERGIC-53/LMAN1. forming multimeric complexes essential for cargo recognition and packaging. Dysregulation of ERGIC3 has been linked to disrupted protein secretion, ER stress, and autophagy, highlighting its broader role in cellular homeostasis.
Recombinant ERGIC3 protein is typically produced using mammalian or bacterial expression systems, often tagged with affinity markers (e.g., His-tag) for purification. Its applications span *in vitro* studies of ER-Golgi trafficking mechanisms, protein-protein interaction assays, and screening for modulators of secretory pathways. Additionally, ERGIC3’s association with diseases, including cancer and neurodegenerative disorders, positions it as a potential biomarker or therapeutic target. Research continues to unravel its precise molecular functions and disease relevance, underscoring its importance in cell biology and translational medicine.
(Word count: 248)
×
